CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: As observed on the K562 cell line, imatinib treatment decreased the expression of miR-21 and increased the expression of PDCD4 mRNA in CD34+ cells prepared from four CML patients (Figure 7A), although these effects were observed at 5μM imatinib (and not at 1μM).